Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Akanksha Bakshi

StageZero Life Sciences Partners With DiagnoseAtHome To Offer Multi-Cancer Blood Test

StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSFhas partnered with DiagnoseAtHome, a multichannel health technology company specializing in at-home health and laboratory testing solutions.

What Happened: Through the partnership, StageZero will make its multi-cancer blood test, Aristotle, available to DiagnoseAtHome's patients in Canada and the U.S.

Built on StageZero's proprietary mRNA gene expression technology platform, Aristotle is a next-generation test that simultaneously screens for multiple cancers from a single blood sample.

Why It's Important: DiagnoseAtHome offers accessible at-home health and lab testing solutions, allowing businesses, organizations, and healthcare providers to provide safe, accurate, and discreet lab testing to patients as an alternative to in-person laboratory visits.

Price Action: SZLS shares are trading higher by 22.22% at C$0.11 on TSX on the last check Wednesday.

Photo Via Company

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.